ClinicalTrials.gg
RecruitingNCT05749588Updated Apr 16, 2026

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

A Phase 2 interventional study of A1: SHR-A1811 and A2: SHR-A1811 with Camrelizumab with famitinib in Triple-negative Breast Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing camrelizumab in Triple Negative Breast Neoplasms — 11 open to participants now, 12 under way, 4 of them phase 3. camrelizumab · Triple Negative Breast Neoplasms.

Planned enrollment
9th of 21
120 · median 90
Started
2023
with 3 others
Phase 2
9 of 21
4 open now
Primary completion
2027-12
later than 7 of 11 live
Registered
14th of 21
by date
Lead sponsor
9 of 21
Fudan University

Among the 21 studies testing camrelizumab in Triple Negative Breast Neoplasms, this one is the 9th largest by planned enrollment, is one of 4 that started in 2023, is one of 9 in phase 2, reaches primary completion later than 7 of the 11 other live ones, and was the 14th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

11 of the 21 studies testing camrelizumab in Triple Negative Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing camrelizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.

Read the detailed description

This is a Phase II, open-label, Single-center platform study,Based on FUSCC four TNBC subtypes and the results of the previous FUTURE trial, the investigators designed this platform trial, which for combined the TNBC subtyping and genomic sequencing-guided precision targeted therapy for refractory metastatic TNBC patients. In this trial, refractory mTNBC patients eligible for inclusion can be divided into various precision treatment group according to molecular typing and subtyping to evaluate the efficacy and safety of multiple precision targeted treatment. The research therapy arm can be updated with the update of basic translational research in our center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs.

03

Conditions studied

  • Triple-negative Breast Cancer

Keywords

  • TNBC
  • Molecular Subtype
  • Precision Treatment
  • Platform Study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female aged ≥18 years;
  2. TNBC invasive breast cancer confirmed by histology (specific definition: ER \<1% positive tumor cells by immunohistochemistry are defined as ER negative, PR \<1% positive tumor cells are defined as PR negative, 0-1+ or HER2 ++ but negative by FISH without amplification was defined as HER2 negative); Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent breast cancer;
  3. Progression after at least one prior therapeutic regimens for advanced/metastatic TNBC
  4. At least one according to 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has not received radiotherapy);
  5. The functions of the main organs are basically normal and meet the following conditions:

    i. Blood routine examination criteria shall meet: HB ≥90 g/L (no blood transfusion within 14 days); The ANC acuity 1.5 x 10\^9 /L; acuity 75 x 10\^9 /L;

    ii. Biochemical tests should meet the following criteria: ≤1.5× (upper limit of normal value); and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1×ULN, endogenous > 50 ml/min (Cockcroft-Gault formula);

  6. They have not received radiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study, and have recovered from the acute toxicity of previous treatment (if surgery was performed, the wound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity;
  7. score ≤1, and ≥3 months;
  8. Fertile female subjects were required to use a medically approved method during the study treatment period and for at least 3 months after the last use of the study drug;
  9. Subjects volunteered to join the study, signed , had good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Radiotherapy (except for palliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment, except bisphosphonate (which can be used for bone );
  2. Uncontrolled central nervous system metastases (indicating symptomatic or symptomatic treatment with or mannitol);
  3. A history of or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6 months;
  4. Persistent grade 1 or higher adverse reactions caused by previous treatments. The exception to this is hair loss or something the researchers don't think should be ruled out. Such cases should be clearly documented in the investigator's notes;
  5. Underwent major surgery (except minor outpatient procedures, such as placement of vascular access) within 3 weeks of the first course of trial treatment;
  6. Pregnant or lactating patients;
  7. (except basal cell carcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5 years.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    IM/HER2-low

    If patients were triple-negative breast cancer with IM subtype and HER2-low-positive

    Drug: A1: SHR-A1811 · Drug: A2: SHR-A1811 with Camrelizumab with famitinib

  • Experimental
    IM/HER2-0

    If patients were triple-negative breast cancer with IM subtype and HER2-zero

    Drug: B1: TROP2 ADC · Drug: B2: TROP2 ADC with Camrelizumab

  • Experimental
    BLIS / HER2-low

    If patients were triple-negative breast cancer with BLIS subtype and HER2-low-positive

    Drug: C1: SHR-A1811 · Drug: C2: SHR-A1811 with BP102

  • Experimental
    BLIS /HER2-0

    If patients were triple-negative breast cancer with BLIS subtype and HER2-zero

    Drug: D1: TROP2 ADC · Drug: D2: TROP2 ADC with BP102

  • Experimental
    LAR / HER2-low

    If patients were triple-negative breast cancer with LAR subtype and HER2-low-positive

    Drug: E1: SHR-A1811 · Drug: E2: SHR-A1811 with everolimus

  • Experimental
    LAR /HER2-0

    If patients were triple-negative breast cancer with LAR subtype and HER2-zero

    Drug: F1: TROP2 ADC

  • Experimental
    MES/ HER2-low

    If patients were triple-negative breast cancer with MES subtype and HER2-low-positive

    Drug: G1: SHR-A1811

  • Experimental
    MES /HER2-0

    If patients were triple-negative breast cancer with MES subtype and HER2-zero

    Drug: H1: TROP2 ADC

  • Experimental
    All-Comer/TQB2102 plus TQB2868

    Drug: TQB2102 with TQB2868

Interventions

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1)

    Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 3 years)

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time to progressive disease (according to RECIST1.1)

    Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 3 years)

  2. Duration of Response (DoR)

    Duration of whose best outcome is complete remission or partial remission (according to RECIST1.1)

    Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study(approximately 3 years)

  3. Disease Control Rate (DCR)

    The proportion of patients with the best overall response of CR, PR, or stable disease (SD)

    Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study(approximately 3 years)

  4. Overall Survival (OS)

    Time to death due to any cause

    Time frame: Randomization to death from any cause, through the end of study (approximately 3 years)

  5. CTCAE scale (V5.0)

    To evaluate the rate of adverse effects of patient by the standard CTCAE scale (V5.0)

    Time frame: Up to One Year during follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 57 months is close to that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2023
First posted
Mar 1, 2023
StartActual
Mar 30, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05749588
Lead sponsor
Fudan University
Responsible party
Zhimin Shao (Professor, Fudan University) — Principal investigator
First posted
Mar 1, 2023
Start date
Mar 30, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 16, 2026

Study contacts

Zhimin Shao, M.D.
Contact
zhimingshao@yahoo.com
+86-021-64175590 ext. 88807
Yin Liu, M.D.
Contact
liuyinfudan@163.com
+86-021-64175590 ext. 88603
Zhimin Shao, M.D.
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab rezetecan · Camrelizumab · Famitinib · BP102 · Everolimus · Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 · Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868

Start the discussion